theobromine has been researched along with Intermittent Claudication in 59 studies
Theobromine: 3,7-Dimethylxanthine. The principle alkaloid in Theobroma cacao (the cacao bean) and other plants. A xanthine alkaloid that is used as a bronchodilator and as a vasodilator. It has a weaker diuretic activity than THEOPHYLLINE and is also a less powerful stimulant of smooth muscle. It has practically no stimulant effect on the central nervous system. It was formerly used as a diuretic and in the treatment of angina pectoris and hypertension. (From Martindale, The Extra Pharmacopoeia, 30th ed, pp1318-9)
theobromine : A dimethylxanthine having the two methyl groups located at positions 3 and 7. A purine alkaloid derived from the cacao plant, it is found in chocolate, as well as in a number of other foods, and is a vasodilator, diuretic and heart stimulator.
Intermittent Claudication: A symptom complex characterized by pain and weakness in SKELETAL MUSCLE group associated with exercise, such as leg pain and weakness brought on by walking. Such muscle limpness disappears after a brief rest and is often relates to arterial STENOSIS; muscle ISCHEMIA; and accumulation of LACTATE.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The efficacy and safety of pentoxifylline (400 mg tid orally) and acenocoumarol, administered singly or in combination, in the treatment of intermittent claudication associated with chronic occlusive arterial disease were evaluated in a multi-center, randomized, factorial, blind clinical trial involving 146 patients." | 9.06 | Acenocoumarol and pentoxifylline in intermittent claudication. A controlled clinical study. The APIC Study Group. ( Basevi, P; Dettori, AG; Di Lecce, C; Manotti, C; Moratti, A; Paolicelli, M; Pini, M; Quintavalla, R, 1989) |
| "The effects of pentoxifylline on intermittent claudication were evaluated at a dose of 1200 mg/day in an open-label twelve-week study on geriatric patients with chronic occlusive arterial disease (COAD)." | 9.06 | Efficacy and safety of pentoxifylline in geriatric patients with intermittent claudication. ( Cobert, BL; Cohn, JB; Crowder, JE; Hryniewicki, SW; Morgan, DL; Piccirillo, RT; Savitsky, JP; Slywka, J; Wilcox, CS, 1989) |
| "Pentoxifylline has been shown to improve treadmill walking distances under blinded, controlled conditions in patients with intermittent claudication." | 9.06 | Effects of pentoxifylline on severe intermittent claudication. ( Gillings, D; Reich, T, 1987) |
| "Ten patients with Stage II chronic arterial occlusive disease (intermittent claudication) took part in a randomized, intraindividual crossover study involving acute intravenous administration of 200 mg pentoxifylline or physiological saline solution (placebo)." | 9.06 | Influence of pentoxifylline on muscle tissue oxygen tension (pO2) of patients with intermittent claudication before and after pedal ergometer exercise. ( Ehrly, AM; Saeger-Lorenz, K, 1987) |
| "Pentoxifylline, a methyl xanthine analogue was evaluated for treatment of intermittent claudication in a double-blind placebo controlled parallel group study in seven centers in the United States." | 9.05 | Pentoxifylline in the treatment of intermittent claudication of the lower limbs. ( Cutler, BC; Lee, BY; Porter, JM; Reich, T; Reichle, FA; Scogin, JT; Strandness, DE, 1984) |
| "The influence of the xanthine derivative pentoxifylline ('Trental' or BL191; Hoechst-Roussel) on exercise tolerance was measured in 38 subjects with stable, severe to moderately severe, intermittent claudication who completed a randomised, double-blind, placebo controlled, cross-over clinical trial." | 9.05 | Intermittent claudication: a double-blind crossover trial of pentoxifylline. ( Alderman, M; Chivers, D; Dupont, P; Gallus, AS; Gleadow, F; Morley, AA; Walsh, J; Wenzel, A, 1985) |
| "Pentoxifylline is approved by the Food and Drug Administration for the treatment of patients with intermittent claudication on the basis of chronic occlusive arterial disease of the limbs." | 8.77 | Pentoxifylline: a new agent for intermittent claudication. ( Baker, DE; Campbell, RK, 1985) |
| "We have previously shown that pentoxifylline, a drug used in intermittent claudication, causes depolymerization of actin in leukocytes in vitro." | 7.68 | Effects of pentoxifylline administration on blood viscosity and leukocyte cytoskeletal function in patients with intermittent claudication. ( Cohen, HJ; Crawford, J; Currie, MS; Rao, KM; Simel, DL, 1990) |
| "All patients who had intermittent claudication (IC) over an 18-month period were given prescriptions for pentoxifylline (PTFX) 400 mg, three times daily." | 7.67 | The effects of pentoxifylline on patients with intermittent claudication. ( Green, RM; McNamara, J, 1988) |
| "Porter et al have reported that pentoxifylline shows statistically significant superiority over placebo in a seven-center, double-blind, parallel group, randomized trial of outpatients with intermittent claudication secondary to chronic occlusive arterial disease." | 7.67 | Another look at the pentoxifylline efficacy data for intermittent claudication. ( Gillings, D; Koch, G; Reich, T; Stager, WJ, 1987) |
| " The positive results derived from pentoxifylline treatment are significant because, for the first time, treadmill testing can prove the effectiveness of a hemorheologic drug, such as pentoxifylline, in the treatment of patients with intermittent claudication." | 7.66 | Peripheral vasodilators versus pentoxifylline for the treatment of intermittent claudication. ( Aviado, DM, 1983) |
| " The dosage was 3 tablets of either formulation t." | 6.65 | Placebo controlled double blind study with pentoxifylline of walking performance in patients with intermittent claudication. ( Di Perri, T; Guerrini, M, 1983) |
| "To review the evidence for efficacy of three contemporary treatments for intermittent claudication: pentoxifylline, exercise programs, and smoking cessation." | 6.16 | Conservative management of intermittent claudication. ( Radack, K; Wyderski, RJ, 1990) |
| "The efficacy and safety of pentoxifylline (400 mg tid orally) and acenocoumarol, administered singly or in combination, in the treatment of intermittent claudication associated with chronic occlusive arterial disease were evaluated in a multi-center, randomized, factorial, blind clinical trial involving 146 patients." | 5.06 | Acenocoumarol and pentoxifylline in intermittent claudication. A controlled clinical study. The APIC Study Group. ( Basevi, P; Dettori, AG; Di Lecce, C; Manotti, C; Moratti, A; Paolicelli, M; Pini, M; Quintavalla, R, 1989) |
| "The effects of pentoxifylline on intermittent claudication were evaluated at a dose of 1200 mg/day in an open-label twelve-week study on geriatric patients with chronic occlusive arterial disease (COAD)." | 5.06 | Efficacy and safety of pentoxifylline in geriatric patients with intermittent claudication. ( Cobert, BL; Cohn, JB; Crowder, JE; Hryniewicki, SW; Morgan, DL; Piccirillo, RT; Savitsky, JP; Slywka, J; Wilcox, CS, 1989) |
| "The efficacy of Trental (pentoxifylline) in the treatment of intermittent claudication was evaluated in 14 double-blind randomized studies, involving 475 patients with chronic occlusive vascular disease." | 5.06 | On the assessment of the efficacy of pentoxifylline (Trental). ( Müller, R; Rössner, M, 1987) |
| "Pentoxifylline has been shown to improve treadmill walking distances under blinded, controlled conditions in patients with intermittent claudication." | 5.06 | Effects of pentoxifylline on severe intermittent claudication. ( Gillings, D; Reich, T, 1987) |
| "Ten patients with Stage II chronic arterial occlusive disease (intermittent claudication) took part in a randomized, intraindividual crossover study involving acute intravenous administration of 200 mg pentoxifylline or physiological saline solution (placebo)." | 5.06 | Influence of pentoxifylline on muscle tissue oxygen tension (pO2) of patients with intermittent claudication before and after pedal ergometer exercise. ( Ehrly, AM; Saeger-Lorenz, K, 1987) |
| "Pentoxifylline, a methyl xanthine analogue was evaluated for treatment of intermittent claudication in a double-blind placebo controlled parallel group study in seven centers in the United States." | 5.05 | Pentoxifylline in the treatment of intermittent claudication of the lower limbs. ( Cutler, BC; Lee, BY; Porter, JM; Reich, T; Reichle, FA; Scogin, JT; Strandness, DE, 1984) |
| "Twenty-six patients with severe short-distance claudication underwent a 24-week, randomized, double-blind, parallel-group evaluation of the efficacy of pentoxifylline in the treatment of intermittent claudication." | 5.05 | Pharmacologic treatment of intermittent claudication. ( Bauer, GM; Porter, JM, 1982) |
| "The influence of the xanthine derivative pentoxifylline ('Trental' or BL191; Hoechst-Roussel) on exercise tolerance was measured in 38 subjects with stable, severe to moderately severe, intermittent claudication who completed a randomised, double-blind, placebo controlled, cross-over clinical trial." | 5.05 | Intermittent claudication: a double-blind crossover trial of pentoxifylline. ( Alderman, M; Chivers, D; Dupont, P; Gallus, AS; Gleadow, F; Morley, AA; Walsh, J; Wenzel, A, 1985) |
| "Pentoxifylline is approved by the Food and Drug Administration for the treatment of patients with intermittent claudication on the basis of chronic occlusive arterial disease of the limbs." | 4.77 | Pentoxifylline: a new agent for intermittent claudication. ( Baker, DE; Campbell, RK, 1985) |
| "Pentoxifylline was significantly more effective than the placebo in increasing both the initial and absolute claudication distance (ICD and ACD) in patients with peripheral chronic occlusive arterial disease (COAD)." | 3.76 | Pentoxifylline (Trental)--a new drug for the treatment of peripheral chronic occlusive arterial disease. ( Aggarwal, KK; Chopra, HK; Chopra, KL; Parashar, SK, 1988) |
| "We have previously shown that pentoxifylline, a drug used in intermittent claudication, causes depolymerization of actin in leukocytes in vitro." | 3.68 | Effects of pentoxifylline administration on blood viscosity and leukocyte cytoskeletal function in patients with intermittent claudication. ( Cohen, HJ; Crawford, J; Currie, MS; Rao, KM; Simel, DL, 1990) |
| "All patients who had intermittent claudication (IC) over an 18-month period were given prescriptions for pentoxifylline (PTFX) 400 mg, three times daily." | 3.67 | The effects of pentoxifylline on patients with intermittent claudication. ( Green, RM; McNamara, J, 1988) |
| "Porter et al have reported that pentoxifylline shows statistically significant superiority over placebo in a seven-center, double-blind, parallel group, randomized trial of outpatients with intermittent claudication secondary to chronic occlusive arterial disease." | 3.67 | Another look at the pentoxifylline efficacy data for intermittent claudication. ( Gillings, D; Koch, G; Reich, T; Stager, WJ, 1987) |
| " The positive results derived from pentoxifylline treatment are significant because, for the first time, treadmill testing can prove the effectiveness of a hemorheologic drug, such as pentoxifylline, in the treatment of patients with intermittent claudication." | 3.66 | Peripheral vasodilators versus pentoxifylline for the treatment of intermittent claudication. ( Aviado, DM, 1983) |
| "In an open clinical trial 14 patients with intermittent claudication caused by an obliteration of the femoral artery received 400 mg pentoxifylline 3 times daily over a period of 6 months." | 3.66 | [The influence of chronic pentroxifylline medication on ergometric and hemodynamic parameters in intermittent claudication (author's transl)]. ( Brock, FE; Nobbe, F; Rudofsky, G; Ulrich, M, 1979) |
| " The dosage was 3 tablets of either formulation t." | 2.65 | Placebo controlled double blind study with pentoxifylline of walking performance in patients with intermittent claudication. ( Di Perri, T; Guerrini, M, 1983) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 55 (93.22) | 18.7374 |
| 1990's | 4 (6.78) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aviado, DM | 2 |
| Skovborg, F | 1 |
| Bonde-Petersen, F | 1 |
| Bloch, I | 1 |
| Christensen, E | 1 |
| Donaldson, DR | 1 |
| Hall, TJ | 1 |
| Kester, RC | 1 |
| Ramsden, CW | 1 |
| Wiggins, PA | 1 |
| Perhoniemi, V | 1 |
| Salmenkivi, K | 1 |
| Sundberg, S | 1 |
| Johnsson, R | 1 |
| Gordin, A | 1 |
| Reich, T | 4 |
| Cutler, BC | 1 |
| Lee, BY | 3 |
| Porter, JM | 4 |
| Reichle, FA | 2 |
| Scogin, JT | 2 |
| Strandness, DE | 2 |
| Roekaerts, F | 1 |
| Deleers, L | 1 |
| Dettelbach, HR | 1 |
| Strano, A | 1 |
| Davi, G | 1 |
| Avellone, G | 1 |
| Novo, S | 1 |
| Pinto, A | 1 |
| Petruzzi, E | 1 |
| Bucalossi, A | 1 |
| Corri, S | 1 |
| Marsilii, A | 1 |
| Di Noto, C | 1 |
| Di Perri, T | 2 |
| Guerrini, M | 1 |
| Cutler, BS | 1 |
| Bauer, GM | 1 |
| Nobbe, F | 2 |
| Rudofsky, G | 2 |
| Brock, FE | 1 |
| Ulrich, M | 1 |
| Völker, D | 1 |
| Radack, K | 1 |
| Wyderski, RJ | 1 |
| Ambrus, JL | 1 |
| Stadler, S | 1 |
| Bannerman, R | 1 |
| Rao, KM | 1 |
| Simel, DL | 1 |
| Cohen, HJ | 1 |
| Crawford, J | 1 |
| Currie, MS | 1 |
| AbuRahma, AF | 1 |
| Woodruff, BA | 1 |
| Weinholdt, T | 1 |
| Schwartz, RW | 1 |
| Logan, NM | 1 |
| Johnson, PJ | 1 |
| Strodel, WE | 1 |
| Fine, JG | 1 |
| Kazmers, A | 1 |
| Hyde, GL | 1 |
| Dettori, AG | 1 |
| Pini, M | 1 |
| Moratti, A | 1 |
| Paolicelli, M | 1 |
| Basevi, P | 1 |
| Quintavalla, R | 1 |
| Manotti, C | 1 |
| Di Lecce, C | 1 |
| Haussler, KF | 1 |
| Künkel, HP | 1 |
| Schneider-May, H | 1 |
| Spengel, F | 1 |
| Symann, O | 1 |
| Werner, HJ | 1 |
| Crowder, JE | 1 |
| Cohn, JB | 1 |
| Savitsky, JP | 3 |
| Morgan, DL | 1 |
| Slywka, J | 1 |
| Cobert, BL | 1 |
| Hryniewicki, SW | 1 |
| Piccirillo, RT | 1 |
| Wilcox, CS | 1 |
| Lindgärde, F | 1 |
| Jelnes, R | 1 |
| Björkman, H | 1 |
| Adielsson, G | 1 |
| Kjellström, T | 1 |
| Palmquist, I | 1 |
| Stavenow, L | 1 |
| Gadeholt, G | 1 |
| Taylor, LM | 1 |
| Chopra, HK | 1 |
| Chopra, KL | 1 |
| Aggarwal, KK | 1 |
| Parashar, SK | 1 |
| Cameron, HA | 1 |
| Waller, PC | 1 |
| Ramsay, LE | 1 |
| Roeren, T | 1 |
| LeVeen, RF | 1 |
| Nugent, L | 1 |
| Johnson, G | 1 |
| Rössner, M | 1 |
| Müller, R | 1 |
| Gillings, D | 2 |
| Kiesewetter, H | 1 |
| Blume, J | 1 |
| Jung, F | 1 |
| Gerhards, M | 1 |
| Leipnitz, G | 1 |
| Hawkins, ES | 1 |
| Ribeiro, HA | 1 |
| Reilly, DT | 2 |
| Quinton, DN | 1 |
| Barrie, WW | 1 |
| Green, RM | 1 |
| McNamara, J | 1 |
| Matrai, A | 1 |
| Ernst, E | 1 |
| Gómez Reyes, D | 1 |
| Rojas Hidalgo, E | 1 |
| Thomas, JH | 1 |
| Swannack, CJ | 1 |
| McAnaw, M | 1 |
| Klein, S | 1 |
| Kinnaman, ML | 1 |
| Iliopoulos, JI | 1 |
| Hermreck, AS | 1 |
| Pierce, GE | 1 |
| Simpson, LO | 2 |
| Ehrly, AM | 1 |
| Saeger-Lorenz, K | 1 |
| Loyd, RG | 1 |
| Prian, GW | 1 |
| Gomez, H | 1 |
| Laub, J | 1 |
| Mertz, GH | 1 |
| Spittell, JA | 1 |
| Johnson, WC | 1 |
| Sentissi, JM | 1 |
| Baldwin, D | 1 |
| Hamilton, J | 1 |
| Dion, J | 1 |
| Hartshorn, JC | 1 |
| Deans, KW | 1 |
| Koch, G | 1 |
| Stager, WJ | 1 |
| Pierce, WL | 1 |
| Crowhurst, JA | 1 |
| Caneva, RG | 1 |
| Gallus, AS | 1 |
| Gleadow, F | 1 |
| Dupont, P | 1 |
| Walsh, J | 1 |
| Morley, AA | 1 |
| Wenzel, A | 1 |
| Alderman, M | 1 |
| Chivers, D | 1 |
| Baker, DE | 1 |
| Campbell, RK | 1 |
| Spittel, JA | 1 |
| Berkowitz, P | 1 |
| May, GS | 1 |
| Brobst, J | 1 |
| McCann, WJ | 1 |
| Pepper, GA | 1 |
| Dammann, C | 1 |
6 reviews available for theobromine and Intermittent Claudication
| Article | Year |
|---|---|
Clinical considerations and treatment of diabetic angiopathy.
Topics: Adult; Arterial Occlusive Diseases; Coronary Disease; Diabetic Angiopathies; Humans; Intermittent Cl | 1979 |
Conservative management of intermittent claudication.
Topics: Double-Blind Method; Exercise Therapy; Humans; Intermittent Claudication; Locomotion; Meta-Analysis | 1990 |
Pentoxifylline (Trental)--a new drug for the treatment of peripheral chronic occlusive arterial disease.
Topics: Administration, Oral; Adult; Aged; Arterial Occlusive Diseases; Clinical Trials as Topic; Female; Hu | 1988 |
[Treatment of vascular diseases of the extremities using pentoxifylline].
Topics: Aminophylline; Arteriosclerosis Obliterans; Clinical Trials as Topic; Drug Evaluation; Humans; Inter | 1988 |
Pentoxifylline review.
Topics: Aminophylline; Biomechanical Phenomena; Humans; Intermittent Claudication; Pentoxifylline; Theobromi | 1987 |
Pentoxifylline: a new agent for intermittent claudication.
Topics: Delayed-Action Preparations; Half-Life; Humans; Intermittent Claudication; Kinetics; Pentoxifylline; | 1985 |
29 trials available for theobromine and Intermittent Claudication
| Article | Year |
|---|---|
[Intermittent claudication treated with pentoxifylline. A controlled trial].
Topics: Aged; Blood Viscosity; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Intermittent C | 1983 |
Does oxpentifylline ('Trental') have a place in the treatment of intermittent claudication?
Topics: Adult; Aged; Blood Viscosity; Clinical Trials as Topic; Double-Blind Method; Erythrocyte Membrane; F | 1984 |
Effects of flunarizine and pentoxifylline on walking distance and blood rheology in claudication.
Topics: Aged; Arteriosclerosis; Blood Pressure; Blood Viscosity; Cinnarizine; Clinical Trials as Topic; Doub | 1984 |
Pentoxifylline in the treatment of intermittent claudication of the lower limbs.
Topics: Clinical Trials as Topic; Female; Humans; Intermittent Claudication; Male; Middle Aged; Pentoxifylli | 1984 |
Trental 400 in the treatment of intermittent claudication: results of long-term, placebo-controlled administration.
Topics: Aged; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Intermittent Claudication; Male | 1984 |
Double-blind, crossover study of the clinical efficacy and the hemorheological effects of pentoxifylline in patients with occlusive arterial disease of the lower limbs.
Topics: Adenosine Diphosphate; Aged; Blood Flow Velocity; Blood Viscosity; Cholesterol; Clinical Trials as T | 1984 |
Pentoxifylline for intermittent claudication.
Topics: Clinical Trials as Topic; Double-Blind Method; Humans; Intermittent Claudication; Pentoxifylline; Th | 1984 |
Placebo controlled double blind study with pentoxifylline of walking performance in patients with intermittent claudication.
Topics: Adult; Aged; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Intermittent Claudicatio | 1983 |
Pentoxifylline efficacy in the treatment of intermittent claudication: multicenter controlled double-blind trial with objective assessment of chronic occlusive arterial disease patients.
Topics: Aged; Arterial Occlusive Diseases; Chronic Disease; Clinical Trials as Topic; Double-Blind Method; E | 1982 |
Pharmacologic treatment of intermittent claudication.
Topics: Double-Blind Method; Drug Evaluation; Erythrocytes; Female; Humans; Intermittent Claudication; Male; | 1982 |
[Treatment of arterial diseases with trental 400. Results of a double-blind study].
Topics: Arterial Occlusive Diseases; Double-Blind Method; Drug Evaluation; Humans; Intermittent Claudication | 1978 |
Conservative management of intermittent claudication.
Topics: Double-Blind Method; Exercise Therapy; Humans; Intermittent Claudication; Locomotion; Meta-Analysis | 1990 |
Acenocoumarol and pentoxifylline in intermittent claudication. A controlled clinical study. The APIC Study Group.
Topics: Acenocoumarol; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Combination; Extremities | 1989 |
Intravenous treatment of chronic peripheral occlusive arterial disease: a double-blind, placebo-controlled, randomized, multicenter trial of pentoxifylline.
Topics: Adult; Aged; Arterial Occlusive Diseases; Blood Pressure; Clinical Trials as Topic; Double-Blind Met | 1989 |
Efficacy and safety of pentoxifylline in geriatric patients with intermittent claudication.
Topics: Aged; Arterial Occlusive Diseases; Blood Pressure; Chronic Disease; Clinical Trials as Topic; Electr | 1989 |
Conservative drug treatment in patients with moderately severe chronic occlusive peripheral arterial disease. Scandinavian Study Group.
Topics: Aged; Arterial Occlusive Diseases; Blood Pressure; Double-Blind Method; Female; Humans; Intermittent | 1989 |
Pentoxifylline (Trental)--a new drug for the treatment of peripheral chronic occlusive arterial disease.
Topics: Administration, Oral; Adult; Aged; Arterial Occlusive Diseases; Clinical Trials as Topic; Female; Hu | 1988 |
Drug treatment of intermittent claudication: a critical analysis of the methods and findings of published clinical trials, 1965-1985.
Topics: Clinical Trials as Topic; Exercise Test; Female; Humans; Hydrocarbons, Chlorinated; Intermittent Cla | 1988 |
[Treatment of vascular diseases of the extremities using pentoxifylline].
Topics: Aminophylline; Arteriosclerosis Obliterans; Clinical Trials as Topic; Drug Evaluation; Humans; Inter | 1988 |
On the assessment of the efficacy of pentoxifylline (Trental).
Topics: Animals; Cats; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Intermittent Claudicat | 1987 |
Effects of pentoxifylline on severe intermittent claudication.
Topics: Aged; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Intermittent Claudication; Loco | 1987 |
[Training by walking and drug therapy of peripheral arterial occlusive disease].
Topics: Aged; Arterial Occlusive Diseases; Clinical Trials as Topic; Combined Modality Therapy; Double-Blind | 1987 |
A controlled trial of pentoxifylline (Trental 400) in intermittent claudication: clinical, haemostatic and rheological effects.
Topics: Adult; Aged; Blood Viscosity; Clinical Trials as Topic; Double-Blind Method; Erythrocyte Deformabili | 1987 |
Pentoxifylline and intermittent claudication.
Topics: Erythrocyte Deformability; Humans; Intermittent Claudication; Pentoxifylline; Theobromine | 1987 |
Pentoxifylline and intermittent claudication.
Topics: Erythrocyte Deformability; Humans; Intermittent Claudication; Pentoxifylline; Theobromine | 1987 |
Pentoxifylline and intermittent claudication.
Topics: Erythrocyte Deformability; Humans; Intermittent Claudication; Pentoxifylline; Theobromine | 1987 |
Influence of pentoxifylline on muscle tissue oxygen tension (pO2) of patients with intermittent claudication before and after pedal ergometer exercise.
Topics: Arterial Occlusive Diseases; Chronic Disease; Clinical Trials as Topic; Exercise Test; Humans; Inter | 1987 |
Intermittent claudication: a double-blind crossover trial of pentoxifylline.
Topics: Aged; Blood Flow Velocity; Double-Blind Method; Exercise Test; Female; Humans; Intermittent Claudica | 1985 |
[Experiences with new Cosaldon forms].
Topics: Adult; Aged; Arteriosclerosis; Cholesterol; Dosage Forms; Female; Geriatrics; Humans; Hypertension; | 1969 |
27 other studies available for theobromine and Intermittent Claudication
| Article | Year |
|---|---|
Peripheral vasodilators versus pentoxifylline for the treatment of intermittent claudication.
Topics: Absorption; Adrenergic alpha-Antagonists; Adrenergic beta-Agonists; Ancrod; Double-Blind Method; Dru | 1983 |
Pharmacology of pentoxifylline, a hemorheologic agent for the treatment of intermittent claudication.
Topics: Absorption; Ancrod; Blood Viscosity; Epoprostenol; Erythrocytes; Hemodynamics; History, 20th Century | 1984 |
[Use of pentoxifylline in diabetes with intermittent claudication].
Topics: Cholesterol; Diabetic Angiopathies; Erythrocytes; Fibrinogen; Glycated Hemoglobin; Humans; Intermitt | 1983 |
[The influence of chronic pentroxifylline medication on ergometric and hemodynamic parameters in intermittent claudication (author's transl)].
Topics: Arterial Occlusive Diseases; Exercise Therapy; Femoral Artery; Humans; Hyperemia; Intermittent Claud | 1979 |
Effect of pentoxifylline on carbohydrate metabolism in type II diabetics.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Humans; Intermittent Claudication; Pentoxifylline; Theobro | 1990 |
Effects of pentoxifylline administration on blood viscosity and leukocyte cytoskeletal function in patients with intermittent claudication.
Topics: Actins; Blood Viscosity; Cell Separation; Colchicine; Cytoskeleton; Drug Evaluation; Humans; Immunol | 1990 |
Effects and limitations of pentoxifylline therapy in various stages of peripheral vascular disease of the lower extremity.
Topics: Diabetes Complications; Humans; Intermittent Claudication; Leg; Locomotion; Pentoxifylline; Severity | 1990 |
[Drug therapy in intermittent claudication].
Topics: Drug Information Services; Humans; Intermittent Claudication; Norway; Pentoxifylline; Theobromine | 1989 |
Pentoxifylline increases extremity blood flow in diabetic atherosclerotic patients.
Topics: Arteries; Arteriosclerosis; Diabetes Mellitus; Diabetic Angiopathies; Exercise Test; Female; Humans; | 1989 |
[Drug therapy of intermittent claudication].
Topics: Humans; Intermittent Claudication; Pentoxifylline; Theobromine | 1989 |
Drug treatment of claudication: vasodilators, hemorrheologic agents, and antiserotonin drugs.
Topics: Double-Blind Method; Erythrocyte Deformability; Humans; Intermittent Claudication; Ketanserin; Pento | 1986 |
Photoplethysmographic documentation of improved microcirculation after pentoxifylline therapy.
Topics: Follow-Up Studies; Humans; Intermittent Claudication; Leg; Male; Microcirculation; Middle Aged; Pent | 1988 |
Pentoxifylline and claudication.
Topics: Blood Viscosity; Exercise; Humans; Intermittent Claudication; Pentoxifylline; Theobromine | 1988 |
The effects of pentoxifylline on patients with intermittent claudication.
Topics: Drug Evaluation; Follow-Up Studies; Humans; Intermittent Claudication; Pentoxifylline; Theobromine; | 1988 |
[Improvement in leukocyte rheology with pentoxifylline].
Topics: Humans; Intermittent Claudication; Leukocytes; Membrane Fluidity; Pentoxifylline; Theobromine | 1988 |
[Therapeutic results with xanthine derivatives in the intermittent claudication syndrome in diabetic patients].
Topics: Adult; Aged; Diabetic Angiopathies; Drug Therapy, Combination; Female; Humans; Intermittent Claudica | 1988 |
Determinants of response to pentoxifylline therapy in patients with intermittent claudication.
Topics: Adult; Aged; Blood Pressure; Female; Humans; Intermittent Claudication; Locomotion; Male; Middle Age | 1987 |
Failure of pentoxifylline for end-stage peripheral vascular disease.
Topics: Aged; Aged, 80 and over; Arterial Occlusive Diseases; Coronary Disease; Humans; Intermittent Claudic | 1987 |
Pentoxifylline and vascular disease.
Topics: Humans; Intermittent Claudication; Pentoxifylline; Theobromine; Vascular Diseases | 1986 |
Treatment of claudication with pentoxifylline: are benefits related to improvement in viscosity?
Topics: Blood Viscosity; Drug Evaluation; Exercise Test; Humans; Intermittent Claudication; Pentoxifylline; | 1987 |
Pharmacologic treatment of intermittent claudication with special emphasis on pentoxifylline.
Topics: Humans; Intermittent Claudication; Patient Education as Topic; Pentoxifylline; Theobromine | 1987 |
Another look at the pentoxifylline efficacy data for intermittent claudication.
Topics: Aged; Aged, 80 and over; Exercise Test; Female; Humans; Intermittent Claudication; Male; Middle Aged | 1987 |
Pentoxifylline. A new drug review and case report.
Topics: Aged; Diabetic Neuropathies; Humans; Intermittent Claudication; Male; Pentoxifylline; Theobromine | 1986 |
Hemorheology and therapy of vascular disease.
Topics: Blood Circulation; Humans; Intermittent Claudication; Pentoxifylline; Rheology; Theobromine | 1986 |
Pentoxifylline and intermittent claudication.
Topics: Blood Viscosity; Erythrocyte Deformability; Humans; Intermittent Claudication; Pentoxifylline; Theob | 1985 |
Pentoxifylline treatment of moderate to severe chronic occlusive arterial disease.
Topics: Aged; Arterial Occlusive Diseases; Exercise Test; Humans; Intermittent Claudication; Ischemia; Leg; | 1985 |
New drug for intermittent claudication.
Topics: Humans; Intermittent Claudication; Patient Education as Topic; Pentoxifylline; Theobromine | 1985 |